Literature DB >> 26232871

Differences in central serotoninergic transmission among patients with recent onset, sub-chronic, and chronic schizophrenia as assessed by the loudness dependence of auditory evoked potentials.

Young-Min Park1, Eunjoo Jung2, Hyang Sook Kim3, Sang Woo Hahn4, Seung-Hwan Lee5.   

Abstract

Previous research has shown that abnormalities in serotonin systems are associated with schizophrenia. The loudness dependence of auditory evoked potentials (LDAEP) has been used as a metric of central serotonin activity. The present study aimed to evaluate LDAEP in patients with schizophrenia of differing chronicity. Sixty-four patients with schizophrenia and 50 healthy controls were enrolled in this study. LDAEP and psychometric ratings, such as the positive and negative syndrome scale (PANSS), were measured. The cohort was stratified into three subgroups according to the duration of illness: recent onset (<2years, n=21), sub-chronic (2-9years, n=28), and chronic (≥10years, n=15) groups. The LDAEP differed significantly among the three groups. A post-hoc analysis (Bonferroni) demonstrated that the LDAEP differed significantly between the recent onset and chronic groups (p=0.029), and between the healthy control and chronic groups (p=0.008). Age, sex, dosage of antipsychotics, and smoking did not significantly affect the group differences. In the correlation analysis, there was a significant correlation of LDAEP values with illness duration (r=-0.259, p=0.045). The present study verifies that the LDAEP is related to the duration of illness in patients with schizophrenia. This suggests that central serotonin neurotransmission is changeable, and it may depend on the chronicity of schizophrenia pathology.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Auditory processing; LDAEP; Schizophrenia; Serotonin

Mesh:

Substances:

Year:  2015        PMID: 26232871     DOI: 10.1016/j.schres.2015.07.036

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

1.  Examining the underpinnings of loudness dependence of auditory evoked potentials with positron emission tomography.

Authors:  Rajapillai L I Pillai; Elizabeth A Bartlett; Mala R Ananth; Chencan Zhu; Jie Yang; Greg Hajcak; Ramin V Parsey; Christine DeLorenzo
Journal:  Neuroimage       Date:  2020-03-10       Impact factor: 6.556

2.  Tobacco use is associated with reduced amplitude and intensity dependence of the cortical auditory evoked N1-P2 component.

Authors:  Philippe Jawinski; Nicole Mauche; Christine Ulke; Jue Huang; Janek Spada; Cornelia Enzenbach; Christian Sander; Ulrich Hegerl; Tilman Hensch
Journal:  Psychopharmacology (Berl)       Date:  2016-03-17       Impact factor: 4.530

3.  Association between the loudness dependence of auditory evoked potentials and age in patients with schizophrenia and depression.

Authors:  Kuk-In Jang; Sungkean Kim; Chany Lee; Jeong-Ho Chae
Journal:  J Int Med Res       Date:  2022-07       Impact factor: 1.573

4.  Auditory evoked potential could reflect emotional sensitivity and impulsivity.

Authors:  Ji Sun Kim; Sungkean Kim; Wookyoung Jung; Chang-Hwan Im; Seung-Hwan Lee
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

Review 5.  Diverse definitions of the early course of schizophrenia-a targeted literature review.

Authors:  Richard Newton; Alice Rouleau; Anna-Greta Nylander; Jean-Yves Loze; Henrike K Resemann; Sara Steeves; Benedicto Crespo-Facorro
Journal:  NPJ Schizophr       Date:  2018-10-15

6.  Relationship between Auditory Evoked Potentials and Circadian Preference in Patients with Major Depressive Episodes.

Authors:  Young-Min Park
Journal:  Brain Sci       Date:  2020-06-12

7.  Effect of behavioral inhibition system and childhood emotional neglect on serotonergic activity, negative affect, and rejection sensitivity in non-clinical adults.

Authors:  Min Jin Jin; Wookyoung Jung; Myoung Ho Hyun; Seung-Hwan Lee
Journal:  PLoS One       Date:  2018-11-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.